UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000003716
Receipt number R000004494
Scientific Title Medicinal treatment on symptoms in patients with gastroesophageal reflux disease (GERD) refractory to PPIs. Multicenter, randomized, paralleled controlled study
Date of disclosure of the study information 2010/06/07
Last modified on 2011/05/26 14:45:47

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Medicinal treatment on symptoms in patients with gastroesophageal reflux disease (GERD) refractory to PPIs. Multicenter, randomized, paralleled controlled study

Acronym

Medicinal treatment for patients with PPIs-refractory GERD patients

Scientific Title

Medicinal treatment on symptoms in patients with gastroesophageal reflux disease (GERD) refractory to PPIs. Multicenter, randomized, paralleled controlled study

Scientific Title:Acronym

Medicinal treatment for patients with PPIs-refractory GERD patients

Region

Japan


Condition

Condition

Gastroesophageal reflux disease (GERD)

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate available pharmaceuticals on refractory GERD, we conducted a study to compare efficacy in relieving symptoms by between rikkunshito combined with a standard dose of rabeprazole (RPZ) and a double dose regimen of RPZ in a prospective randomized multi-center trial.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Evaluation of acid reflux-related symptoms using Frequency scale for symptoms of GERD (FSSG)

Key secondary outcomes

Subgroup analysis for age, gender, BMI or endoscopic diagnose


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is considered as a block.

Blocking

YES

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Oral administration of rabeprazole (10mg) combined with rikkunshito
(7.5g) before meals for 28 days

Interventions/Control_2

Oral administration of rabeprazole (20mg)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) GERD patients who were received a treatment of rabeprazole (10 mg once daily) for more than 4 weeks.
2) Patients who were defined as a score of more than 8 points estimated using the frequency scale for the symptoms of gastroesophageal reflux disease (FSSG) after treatment with rabeprazole at standard dose (10 mg, once daily).
3) Patients who are able to administer orally
4) Patients who have signed consent to participate in this research

Key exclusion criteria

1) Patients with GERD which had C or D grade esophagitis diagnosed by endoscopic testing.
2) Patients with serious complications (e.g., hepatic, renal, cardiac, pulmonary, hematological, or metabolic diseases)
3) Patients with abscission of upper gastrointestinal tract
4) Patients who had peptic ulcer (excusing cicatrices) or tumor.
5) Patients with disorder in liver, gallbladder, or pancreas
6) Patients with gastrointestinal bleeding, mechanical ileus, gastrointestinal perforation.
7) Patients who received drugs prohibited for concomitant use during the observation period
8) Patients who were received treatment of rabeprazole (20mg)
9) Patients with psychoneurosis
10) Patients with planning or during treatment of investigational drug
11) Patients with pregnant, considering pregnancy or lactation
12) Patients considered inappropriate by the study investigator

Target sample size

120


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Fujimoto Kazuma

Organization

Saga University Hospital

Division name

Department of Internal Medicine

Zip code


Address

5-1-1, Nabeshima, Saga

TEL

0952-34-2361

Email



Public contact

Name of contact person

1st name
Middle name
Last name Fujimoto Kazuma

Organization

Saga University Hospital

Division name

Department of Internal Medicine

Zip code


Address

5-1-1, Nabeshima, Saga

TEL

0952-34-2361

Homepage URL


Email



Sponsor or person

Institute

Department of Internal Medicine, Saga University Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Osaka City University Hospital
Osaka Medical College Hospital
Gunma University Hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2010 Year 06 Month 07 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2008 Year 04 Month 10 Day

Date of IRB


Anticipated trial start date

2008 Year 04 Month 01 Day

Last follow-up date

2011 Year 03 Month 01 Day

Date of closure to data entry

2011 Year 04 Month 01 Day

Date trial data considered complete

2011 Year 04 Month 01 Day

Date analysis concluded

2011 Year 05 Month 01 Day


Other

Other related information



Management information

Registered date

2010 Year 06 Month 04 Day

Last modified on

2011 Year 05 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004494


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name